253 related articles for article (PubMed ID: 24754826)
1. Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Rosas IO; Dellaripa PF; Lederer DJ; Khanna D; Young LR; Martinez FJ
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S169-77. PubMed ID: 24754826
[TBL] [Abstract][Full Text] [Related]
2. Purpose of the meeting: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Kiley JP
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):i. PubMed ID: 24754819
[No Abstract] [Full Text] [Related]
3. Asthma: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Jackson DJ; Hartert TV; Martinez FD; Weiss ST; Fahy JV
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S139-45. PubMed ID: 24754822
[TBL] [Abstract][Full Text] [Related]
4. Executive Summary: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Busse WW; Erzurum SC; Blaisdell CJ; Noel P
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S123-4. PubMed ID: 24754820
[No Abstract] [Full Text] [Related]
5. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
McEvoy CT; Jain L; Schmidt B; Abman S; Bancalari E; Aschner JL
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S146-53. PubMed ID: 24754823
[TBL] [Abstract][Full Text] [Related]
6. Chronic obstructive pulmonary disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Drummond MB; Buist AS; Crapo JD; Wise RA; Rennard SI
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S154-60. PubMed ID: 24754824
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Pittman JE; Cutting G; Davis SD; Ferkol T; Boucher R
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S161-8. PubMed ID: 24754825
[TBL] [Abstract][Full Text] [Related]
8. Promotion of lung health: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Camargo CA; Budinger GR; Escobar GJ; Hansel NN; Hanson CK; Huffnagle GB; Buist AS
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S125-38. PubMed ID: 24754821
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Austin ED; Kawut SM; Gladwin MT; Abman SH
Ann Am Thorac Soc; 2014 Apr; 11 Suppl 3(Suppl 3):S178-85. PubMed ID: 24754827
[TBL] [Abstract][Full Text] [Related]
10. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
[TBL] [Abstract][Full Text] [Related]
11. Developing a research agenda for primary prevention of chronic lung diseases--an NHLBI perspective.
Kiley J; Gibbons G
Am J Respir Crit Care Med; 2014 Apr; 189(7):762-3. PubMed ID: 24684354
[No Abstract] [Full Text] [Related]
12. Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.
Mackintosh JA; Stainer A; Barnett JL; Renzoni EA
Semin Respir Crit Care Med; 2019 Apr; 40(2):208-226. PubMed ID: 31137061
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
14. Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016.
Ho ATN; Shmelev A; Charbek E
Respir Res; 2020 Jun; 21(1):152. PubMed ID: 32546158
[TBL] [Abstract][Full Text] [Related]
15. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
[TBL] [Abstract][Full Text] [Related]
16. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
17. Lung Cancer development and mortality in interstitial lung disease with and without connective tissue diseases: a five-year Nationwide population-based study.
Choi WI; Lee DY; Choi HG; Lee CW
Respir Res; 2019 Jun; 20(1):117. PubMed ID: 31182103
[TBL] [Abstract][Full Text] [Related]
18. Deciphering Disparities: The NHLBI Program on Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR).
Mensah GA; Murray DM
Ethn Dis; 2023 Dec; DECIPHeR(Spec Issue):1-5. PubMed ID: 38846734
[TBL] [Abstract][Full Text] [Related]
19. National Heart, Lung, and Blood Institute Workshop Summary: Enhancing Opportunities for Training and Retention of a Diverse Biomedical Workforce.
Duncan GA; Lockett A; Villegas LR; Almodovar S; Gomez JL; Flores SC; Wilkes DS; Tigno XT
Ann Am Thorac Soc; 2016 Apr; 13(4):562-7. PubMed ID: 27058184
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice.
Shiomi A; Usui T; Ishikawa Y; Shimizu M; Murakami K; Mimori T
J Immunol; 2014 Jul; 193(2):849-59. PubMed ID: 24951817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
